Sandoz launches Glatopa as first U.S. Copaxone generic

HOLZKIRCHEN, Germany — Sandoz has launched Glatopa, the first U.S. generic of Teva’s Copaxone (glatiramer acetate injection, 20-mg/ml ), a once-daily treatment for multiple sclerosis. The drug was developed in collaboration with Momenta and approved by the FDA in April. 

“Sandoz, together with Momenta, is proud to announce the US market launch of a fully substitutable generic version of this important therapy, following FDA approval,” Sandoz U.S. President Peter Goldschmidt said.

The company is also introducing a patient support service that includes financial assistance for qualifying patients, injection training, and access to nurses for non-clinical questions 24 hours a day.